PharmaExceed

PharmaExceed is an Italian biotechnology company founded in 2017 as a spin-off from the University of Pavia. The company focuses on the development of exosome-based therapies derived from the secretome of mesenchymal stem cells (MSCs) for regenerative medicine and drug delivery. Its flagship platform, Lyosecretome, is a standardized, lyophilized powder containing extracellular vesicles and microvesicles that can be used to treat inflammatory and degenerative conditions. PharmaExceed's pipeline targets diverse therapeutic areas including respiratory, neurological, and musculoskeletal diseases, while also utilizing exosomes as vehicles for nanoparticle-based cancer treatments. The company aims to provide standardized, cell-free alternatives to traditional stem cell therapies.